The purpose of this clinical trial is to assess the effectiveness of Epetraborole, taken once daily, in patient populations with treatment-refractory MAC lung disease.

Eligible patients include those who currently have a positive MAC sputum culture despite receiving a combination regimen of at least 2 antimycobacterial agents administered for at least 6 months.